問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Link to Hospital

  • 1,089

    Total Beds

  • 275

    Total Doctors

  • shengyuan@cgmh.org.tw
  • Lin, Sheng-yuan
  • 02-24329292 #2082
  • 204Keelung CityAn LeNo. 222, Maijin Rd., Anle Dist., Keelung City 204015, Taiwan

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

167Cases

2016-11-13 - 2021-12-13

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Filgotinib

Participate Sites
9Sites

Terminated9Sites

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2016-12-01 - 2021-12-31

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

  • Condition/Disease

    Rheumatoid arthritis

  • Test Drug

    Filgotinib

Participate Sites
12Sites

Terminated11Sites

方耀凡
Linkou Chang Gung Medical Foundation

藍忠亮
China Medical University Hospital-Taipei

未分科

2020-02-27 - 2024-01-31

Phase III

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    (1) Filgotinib; (2) Adalimumab

Participate Sites
13Sites

Terminated13Sites

2013-12-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-05-01 - 2023-05-02

Phase II

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Tipifarnib

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
11Sites

Terminated11Sites

2011-06-01 - 2014-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
8Sites

Terminated8Sites

2012-10-01 - 2015-09-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 10 11 12 13 14 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB